# US 2026/0077056 A1 · Linker-payload compound, conjugates and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077056 A1
- Document ID: US20260077056A1
- Status: Published application
- Kind: A1
- Application number: 19/121,119
- Filed: 2023-10-13
- Published: 2026-03-19
- Earliest claimed: 2022-10-14
- Assignees: Genequantum Healthcare (Suzhou) Co., Ltd.; Genequantum Medicine (Suzhou) Co., Ltd.
- Applicants: Genequantum Healthcare (Suzhou) Co., Ltd.; Genequantum Medicine (Suzhou) Co., Ltd.
- Inventors: Gang QIN; Zhaoxiong CAI; Mingyu HU
- Web page: https://patentgrep.com/patent/US20260077056A1

## CPC

- A61K 47/6883: {Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy}
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07D 493/22: in which the condensed system contains four or more hetero rings
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A linker-payload compound for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof are provided.

## Claims

### Claim 1

A compound having the structure of formula (II)
wherein,
Q is hydrogen or LKb-P;
M is hydrogen or LKa-LKb-P;
provided that Q and M are not simultaneously hydrogen;
each LKa is independently selected from
opSu is
or a mixture thereof;
each LKb is independently L2-L1;
P is a payload which is linked to the L1 moiety;
L1 is Cleavable sequence 1 comprising an amino acid sequence which can be cleaved by enzyme, and Cleavable sequence 1 comprises 1-10 amino acids;
L2 is a bond; or a C2-20 alkylene wherein one or more —CH2— structures in the alkylene is optionally replaced by —CR1R2—, —O—, —(CO)—, —S(═O)2—, —NR3—, —N⊕R4R5—, C4-10 cycloalkylene, C4-10 heterocyclylene, phenylene; wherein the cycloalkylene, heterocyclylene and phenylene are each independently unsubstituted or substituted with at least one substituent selected from halogen, —C1-10 alkyl, —C1-10 haloalkyl, —C1-10 alkylene-NH—R6 and —C1-10 alkylene-O—R7;
Ld2 and each Ld1 are independently a bond; or selected from —NH—C1-20 alkylene-(CO)—, —NH—(PEG); —(CO)—, or is a natural amino acid or oligomeric natural amino acids having a degree of polymerization of 2-10 independently unsubstituted or substituted with -(PEG)j-R8 on the side chain;
-(PEG)i- and -(PEG)j- are each a PEG fragment, which comprises the denoted number of consecutive —(O—C2H4)— structure units or consecutive —(C2H4—O)— structure units, with an optional additional C1-10 alkylene at one terminal;
R1, R2, R3, R4, R5, R6, R7 are each independently selected from hydrogen, halogen, —C1-10 alkyl, —C1-10 haloalkyl, C4-10 cycloalkylene;
R8 is C1-10 alkyl;
n is any integer of 2 to 20;
d is 0, or is any integer of 1 to 6;
each i is independently an integer of 1-100, preferably 1 to 20; preferably each i is independently an integer of 1 to 12; more preferably 2 to 8; particularly 4;
each j is independently an integer of 1-100, preferably 1 to 20; preferably each j is independently an integer of 1 to 12; more preferably 8 to 12; particularly 8 or 12.

### Claim 2 (depends on 1)

The compound of claim 1, wherein P has the structure of formula (i)
wherein,
each of D and D′ is independently selected from R9 and OR9, wherein R9 is H, C1-3 alkyl, or C1-3 haloalkyl;
each of U and U′ is independently H, C1-3 alkoxy, or C1-3 alkyl; or U and U′ taken together are ═CH2;
W is C1-3 alkyl;
each of V and V′ is independently H, C1-3 alkoxy, or C1-3 alkyl; or U and U′ taken together are ═CH2;
X is H or C1-6 alkoxy;
each of Y and Y′ is independently H or C1-3 alkoxy; or Y and Y′ taken together are ═O, ═CH2; and
each of Z and Z′ is independently H or C1-3 alkoxy; or Z and Z′ taken together are ═O, ═CH2;
or a pharmaceutically acceptable salt thereof;
preferably, P has the structure of formula (i-1)
further preferably, P has the structure of formula (ii)
wherein the wavy bond shows the connection site for connection to the L1 moiety.

### Claim 3 (depends on 1)

The compound of claim 1, having the structure of formula (II-i)

### Claim 4 (depends on 1)

The compound of claim 1, selected from

### Claim 5 (depends on 1)

The compound of claim 1, selected from
wherein, each i, i1, i2, i3, i4 is independently an integer of 1-100, preferably 1 to 20; preferably each i, i1, i2, i3, i4 is independently an integer of 1 to 12; more preferably 2 to 8; particularly 4.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Ld2 and each Ld1 are independently a bond or
each k is independently an integer of 1-100, preferably 1 to 20; preferably each k is independently an integer of 1 to 12; more preferably 1 to 7; particularly 1, or 3 or 5.

### Claim 7 (depends on 1)

The compound of claim 1, wherein
Cleavable sequence 1 is selected from GLy-GLy-Phe-GLy, Phe-Lys, Val-Cit, Val-Lys, GLy-Phe-Leu-Gly, Ala-Leu-Ala-Leu, Ala-Ala-Ala, Val-Cit-PABC and the combination thereof; preferably, Cleavable sequence 1 is GLy-GLy-Phe-Gly or Val-Cit-PABC.

### Claim 8 (depends on 1)

The compound of claim 1, wherein
Q is hydrogen; and/or
R8 is C1-6 alkyl, preferably methyl; and/or
n is an integer of 2 to 5, especially 3; and/or
d is 0, or is any integer of 1 to 4; preferably 0, 1, 2 or 3.

### Claim 9 (depends on 1)

The compound of claim 1, selected
each i, i1, i2, i3, i4 is independently an integer of 1-100, preferably 1 to 20; preferably each i, i1, i2, i3, i4 is independently an integer of 1 to 12; more preferably 2 to 8; particularly 4.

### Claim 10

A conjugate having the structure of formula (III):
wherein,
Q is hydrogen or LKb-P;
M is hydrogen or LKa-LKb-P;
provided that Q and M are not simultaneously hydrogen;
A is a targeting molecule which is linked to the Gn moiety of the compound of formula (II); G is glycine;
z is an integer of 1 to 20;
each LKa is independently selected from
opSu is
or a mixture thereof;
each LKb is independently L2-L1;
P is a payload which is linked to the L1 moiety;
L1 is Cleavable sequence 1 comprising an amino acid sequence which can be cleaved by enzyme, and Cleavable sequence 1 comprises 1-10 amino acids;
L2 is a bond; or a C2-20 alkylene wherein one or more —CH2— structures in the alkylene is optionally replaced by —CR1R2—, —O—, —(CO)—, —S(═O)2—, —NR3, —N⊕R4R5, C4-10 cycloalkylene, C4-10 heterocyclylene, phenylene; wherein the cycloalkylene, heterocyclylene and phenylene are each independently unsubstituted or substituted with at least one substituent selected from halogen, —C1-10 alkyl, —C1-10 haloalkyl, —C1-10 alkylene-NH—R6 and —C1-10 alkylene-O—R7;
Ld2 and each Ld1 are independently a bond; or selected from —NH—C1-20 alkylene-(CO)—, —NH—(PEG); —(CO)—, or is a natural amino acid or oligomeric natural amino acids having a degree of polymerization of 2-10 independently unsubstituted or substituted with -(PEG)j-R8 on the side chain;
-(PEG)i- and —(PEG)j- are each a PEG fragment, which comprises the denoted number of consecutive —(O—C2H4)— structure units or consecutive —(C2H4—O)— structure units, with an optional additional C1-10 alkylene at one terminal;
R1, R2, R3, R4, R5, R6, R7 are each independently selected from hydrogen, halogen, —C1-10 alkyl, —C1-10 haloalkyl, C4-10 cycloalkylene;
R8 is C1-10 alkyl;
n is any integer of 2 to 20;
d is 0, or is any integer of 1 to 6;
each i is independently an integer of 1-100, preferably 1 to 20; preferably each i is independently an integer of 1 to 12; more preferably 2 to 8; particularly 4;
each j is independently an integer of 1-100, preferably 1 to 20; preferably each j is independently an integer of 1 to 12; more preferably 8 to 12; particularly 8 or 12.

### Claim 11 (depends on 10)

The conjugate of claim 10, wherein the payload is a cytotoxin or a fragment thereof, with an optional derivatization in order to connect to the L1 moiety;
preferably, the payload is selected from the group consisting of the following compounds or a fragment thereof:
taxanes, maytansinoids, auristatins, epothilones, combretastatin A-4 phosphate, combretastatin A-4 and derivatives thereof, indol-sulfonamides, vinblastines such as vinblastine, vincristine, vindesine, vinorelbine, vinflunine, vinglycinate, anhy-drovinblastine, dolastatin 10 and analogues, halichondrin B, cribulin, indole-3-oxoacetamide, podophyllotoxins, 7-diethylamino-3-(2′-benzoxazolyl)-coumarin (DBC), discodermolide, laulimalide, camptothecins and derivatives thereof, mitoxantrone, mitoguazone, nitrogen mustards, nitrosoureasm, aziridines, benzodopa, carboquone, meturedepa, uredepa, dynemicin, esperamicin, neocarzinostatin, aclacinomycin, actinomycin, antramycin, bleomycins, actinomycin C, carabicin, carminomycin, cardinophyllin, carminomycin, actinomycin D, daunorubicin, detorubicin, adriamycin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, nogalamycin, olivomycin, peplomycin, porfiromycin, puromycin, ferric adriamycin, rodorubicin, rufocromomycin, streptozocin, zinostatin, zorubicin, trichothecene, T-2 toxin, verracurin A, bacillocporin A, anguidine, ubenimex, azaserine, 6-diazo-5-oxo-L-norleucine, dimethyl folic acid, methotrexate, pteropterin, trimetrexate, edatrexate, fludarabine, 6-mercaptopurine, tiamiprine, thioguanine, ancitabine, gemcitabine, enocitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, flutamide, nilutamide, bicalutamide, leuprorelin acetate, protein kinase inhibitors and a proteasome inhibitors; preferably eribulin; and/or
selected from vinblastines, colchicines, taxanes, auristatins, maytansinoids, calicheamicin, doxonubicin, duocarmucin, SN-38, cryptophycin analogue, deruxtecan, duocarmazine, calicheamicin, centanamycin, dolastansine, pyrrolobenzodiazepine, exatecan and derivatives thereof; and/or
selected from auristatins, especially MMAE, MMAF or MMAD; and/or
selected from exatecan and derivatives thereof, such as DX8951f; and/or
selected from DXd-(1) and DXd-(2); preferably DXd-(1).

### Claim 12 (depends on 10)

The conjugate of claim 10, wherein P has the structure of formula (i)
wherein,
each of D and D′ is independently selected from R9 and OR9, wherein R9 is H, C1-3 alkyl, or C1-3 haloalkyl;
each of U and U′ is independently H, C1-3 alkoxy, or C1-3 alkyl; or U and U′ taken together are ═CH2;
W is C1-3 alkyl;
each of V and V′ is independently H, C1-3 alkoxy, or C1-3 alkyl; or U and U′ taken together are ═CH2;
X is H or C1-6 alkoxy;
each of Y and Y′ is independently H or C1-3 alkoxy; or Y and Y′ taken together are ═O, ═CH2; and
each of Z and Z′ is independently H or C1-3 alkoxy; or Z and Z′ taken together are ═O, ═CH2;
or a pharmaceutically acceptable salt thereof;
preferably, P has the structure of formula (i-1)
further preferably, P has the structure of formula (ii)
wherein the wavy bond shows the connection site for connection to the L1 moiety;
and/or
(ii) the targeting molecule is antibody or antigen binding fragment thereof; preferably, antibody is anti-CD19 antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD25 antibody, anti-CD30/TNFRSF8 antibody, anti-CD33 antibody, anti-CD37 antibody, anti-CD44v6 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD71 antibody, anti-CD74 antibody, anti-CD79b antibody, anti-CD117/KITk antibody, anti-CD123 antibody, anti-CD138 antibody, anti-CD142 antibody, anti-CD174 antibody, anti-CD227/MUC1 antibody, anti-CD352 antibody, anti-CLDN18.2 antibody, anti-DLL3 antibody, anti-ErbB2/HER2 antibody, anti-CN33 antibody, anti-GPNMB antibody, anti-ENPP3 antibody, anti-Nectin-4 antibody, anti-EGFRvIII antibody, anti-SLC44A4/AGS-5 antibody, anti-CEACAM5 antibody, anti-PSMA antibody, anti-TIM1 antibody, anti-LY6E antibody, anti-LIV1 antibody, anti-Nectin4 antibody, anti-SLITRK6 antibody, anti-HGFR/cMet antibody, anti-SLAMF7/CS1 antibody, anti-EGFR antibody, anti-BCMA antibody, anti-AXL antibody, anti-NaPi2B antibody, anti-GCC antibody, anti-STEAP1 antibody, anti-MUC16 antibody, anti-Mesothelin antibody, anti-ETBR antibody, anti-EphA2 antibody, anti-5T4 antibody, anti-FOLR1 antibody, anti-LAMP1 antibody, anti-Cadherin 6 antibody, anti-FGFR2 antibody, anti-FGFR3 antibody, anti-CA6 antibody, anti-CanAg antibody, anti-integrin αV antibody, anti-TDGF1 antibody, anti-Ephrin A4 antibody, anti-TROP2 antibody, anti-PTK7 antibody, anti-NOTCH3 antibody, anti-C4.4A antibody, anti-FLT3 antibody, anti-B7H3/4 antibody, anti-Tissue Factor antibody, or anti-ROR1/2 antibody; more preferably, anti-HER2 antibody, anti-FGFR3 antibody, anti-Trop2 antibody, anti-HER3 antibody or anti-FRα antibody; more preferably, the antibody is anti-FGFR3 antibody, anti-Trop2 antibody, anti-HER3 antibody or anti-FRα antibody;
further preferably, the antibody is an anti-human FGFR3 antibody, preferably Ab0206; or an anti-human HER2 antibody, preferably Ab0036 or Ab0001.

### Claim 13 (depends on 10)

The conjugate of claim 10, having the structure of formula (III-i)

### Claim 14 (depends on 10)

The conjugate of claim 10, wherein
the conjugate has the structure of the following formula (III-1):

### Claim 15 (depends on 10)

The conjugate of claim 10, wherein
the conjugate has the structure of the following:
preferably, z is 1 to 4; preferably 2;
each i, i1, i2, i3, i4 is independently an integer of 1-100, preferably 1 to 20; preferably each i, i1, i2, i3, i4 is independently an integer of 1 to 12; more preferably 2 to 8; particularly 4;
each j is independently an integer of 1-100, preferably 1 to 20; preferably each j is independently an integer of 1 to 12; more preferably 8 to 12; particularly 8 or 12;
preferably, n is 3, L2 is —(CH2)p−(CH2)2(CO)—, p is 3, L1 is GGFG or Val-Cit-PABC.

### Claim 16 (depends on 10)

The conjugate of claim 10, wherein
the targeting molecule is an antibody or an antigen binding fragment thereof; the antibody or antigen binding fragment is preferably modified to connect with the Gn moiety in the compound of formula (II);
preferably,
(i) the antibody is an anti-human HER2 antibody or anti-human FGFR3 antibody; and/or
(ii) the Gn moiety in the compound of formula (II) is the recognition sequence of the ligase acceptor substrate of a ligase; and
the antibody is modified to comprises the recognition sequence of the ligase donor substrate in order to connect with the Gn moiety in the compound of formula (II);
preferably,
(a) the ligase is a Sortase selected from Sortase A, Sortase B, Sortase C, Sortase D and Sortase L. plantarum; preferably Sortase A from Staphylococcus aureus; and/or
(b) the recognition sequence of the ligase donor substrate is LPXTGJ, J is absent or is Gm, wherein G is glycine, m is an integer of 1 to 10; preferably, the recognition sequence of the ligase donor substrate is LPXTG or LPETGG; and/or
the connection of LPXTGJ with Gn results in LPXTGn.

### Claim 17 (depends on 10)

The conjugate of claim 10, wherein

### Claim 18 (depends on 10)

A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of a conjugate of claim 10, and at least one pharmaceutically acceptable carrier.

### Claim 19 (depends on 18)

A method for treating a disease, comprising administering the pharmaceutical composition of claim 18 to a subject in need thereof; wherein the disease is a tumor or an autoimmune disease;
preferably the disease is a HER2-positive or FGFR3-positive tumor;
preferably, the HER2-positive tumor is selected from breast cancer, gastric cancer, lung cancer, ovarian cancer, and urothelial cancer;
preferably, the FGFR3-positive tumor is selected from multiple myeloma, bladder cancer, urothelial cancer, and glioblastoma.
